Unlike cancers common in adults, childhood cancers are unlikely to be prevented by screening.
As the population continues to increase over time, the incidence of childhood and adolescent cancer will rise as well, with the burden of years of lost life to childhood cancer falling hardest on low-income countries, according to recent research.
A report, published by The Lancet Oncology, explained the result of a study conducted by Lisa Force and colleagues which evaluated the global burden of childhood cancer in disability-adjusted life-years (DALYs) and considered the loss of healthy life-years to ill health and disability in addition to death.
The study found that high and high-middle sociodemographic index countries accounted for 35% of global childhood and adolescent cancer incidence, yet only 18% of DALYs. However, globally, years of life lost represent 97.3% of DALYs and only 2.7% of years lived with disability, while years lived with disability to total DALYs ranges from 9% in high and high-middle countries to less than 1% in low-middle and low socio-demographic index countries.
“Childhood and adolescent cancer is much less amenable to prevention than many major cancers of adults, for which risk factors can be reduced or even eliminated,” the author explained. “The history of population screening for childhood cancer is not encouraging. The only feasible target was neuroblastoma, but screening led to overdiagnosis of cases that would have regressed without symptoms and had no effect on mortality from the more aggressive forms of this cancer.”
The report suggested that earlier diagnosis through increased public and clinical awareness could result in a short-term rise in global burden for children since fewer cancers would be diagnosed after the age of 20. However, earlier diagnosis could bring substantial reductions in mortality and long-term morbidity, noted the author.
“More than half a century of progress in therapy and supportive care for children with cancer has resulted in impressive gains in survival and corresponding reductions in population mortality rates in high-income countries,” noted the report. “However, this success has come at the price of increased long-term morbidity and mortality among survivors compared with the general population, which must also be counted as part of the cancer burden.”
Improved diagnostic and treatment facilities with universal access, as well as international collaboration are essential for the benefits of early diagnosis to be realized and utilized.
Reference
Stiller C. Global burden of childhood cancer: growing, but controllable [published online July 29,
2019]. Lancet Oncol. doi.org/10.1016/S1470-2045(19)30424-3.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Community Engagement, Culturally Tailored Care as a Gateway to Advancing Health Equity
October 16th 2024Many talks at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference advocated for the adoption of culturally relevant care, the leveraging of community partnerships, and community engagement to build better trust with patients and improve outcomes.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Creating Equitable Cancer Care for Americans of Asian and Pacific Islander Heritage
October 15th 2024Naoto T. Ueno, MD, PhD, FACP, of the University of Hawai’I Cancer Center outlines the underrepresentation in clinical trials, the lack of permanent medical oncologists, and issues of trust affecting care for the populations living in Hawaii.
Read More